دورية أكاديمية
أعرض في EDS

A dosimetric analysis of rectal hydrogel spacer use in patients with recurrent prostate cancer undergoing salvage high-dose-rate brachytherapy.

التفاصيل البيبلوغرافية
العنوان: A dosimetric analysis of rectal hydrogel spacer use in patients with recurrent prostate cancer undergoing salvage high-dose-rate brachytherapy.
المؤلفون: Lee CT; Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA. Electronic address: charles.lee@fccc.edu., Koleoso O; Doctor of Osteopathic Medicine Program, Philadelphia College of Osteopathic Medicine, Philadelphia, PA., Deng M; Department of Biostatistics and Bioinformatics, Fox Chase Cancer Center, Philadelphia, PA., Veltchev I; Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA., Lin T; Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA., Hallman MA; Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA., Horwitz EM; Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA., Wong JK; Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA.
المصدر: Brachytherapy [Brachytherapy] 2023 Sep-Oct; Vol. 22 (5), pp. 586-592. Date of Electronic Publication: 2023 Jun 30.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural
اللغة: English
بيانات الدورية: Publisher: Elsevier, 2002- Country of Publication: United States NLM ID: 101137600 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-1449 (Electronic) Linking ISSN: 15384721 NLM ISO Abbreviation: Brachytherapy Subsets: MEDLINE
أسماء مطبوعة: Original Publication: New York, NY : Elsevier, 2002-
مواضيع طبية MeSH: Brachytherapy*/methods , Prostatic Neoplasms*/radiotherapy, Male ; Humans ; Hydrogels ; Radiotherapy Dosage ; Radiometry ; Rectum
مستخلص: Purpose: We hypothesize rectal hydrogel spacer (RHS) improves rectal dosimetry in patients undergoing salvage high-dose-rate brachytherapy (HDR-BT) for intact, recurrent prostate cancer (PC).
Methods and Materials: A prospectively collected institutional database was queried for recurrent PC patients treated with salvage HDR-BT from September 2015 to November 2021. Patients were offered RHS beginning June 2019. Dosimetric variables were compared between RHS and no-RHS groups for the average of two fractions using Wilcoxon rank-sum tests. Primary outcomes were rectal volume receiving 75% of prescription dose (V75%) and prostate volume receiving 100% of prescription dose (V100%). Generalized estimating equation (GEE) model was used to evaluate the association between other planning variables and rectal V75%.
Results: Forty-one PC patients received salvage HDR-BT, of whom 20 had RHS. All patients received 2400cGy in 2 fractions. Median RHS volume was 6.2cm 3 (Standard deviation [SD]: ± 3.5cm 3 ). Median follow-up was 4 months and 17 months in the RHS and no-RHS groups, respectively. Median rectal V75% with and without RHS were 0.0cm3 (IQR: 0.0-0.0cm3) and 0.06cm3 (IQR: 0.0-0.14cm3), respectively (p<0.001). Median prostate V100% with and without RHS were 98.55% (IQR: 97.86-99.22%) and 97.78% (IQR: 97.50-98.18%), respectively (p = 0.007). RHS, rectum, and prostate volumes did not significantly affect rectal V75% per GEE modeling. There was 10% G1-2 and 5% G3 rectal toxicity in RHS group. There was 9.5% G1-2 and no G3+ rectal toxicities in the no-RHS group.
Conclusions: Absolute improvement in rectal V75% and prostate V100% was significant with RHS in PC patients undergoing salvage HDR-BT, but clinical benefit is marginal.
(Copyright © 2023 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.)
References: J Med Imaging Radiat Oncol. 2021 Jun;65(3):384-397. (PMID: 33855816)
Brachytherapy. 2018 Mar - Apr;17(2):251-258. (PMID: 29241706)
Cancer. 2010 Nov 15;116(22):5226-34. (PMID: 20690197)
Jpn J Clin Oncol. 2007 Feb;37(2):121-6. (PMID: 17255159)
Front Oncol. 2021 Sep 09;11:681448. (PMID: 34568012)
J Med Imaging Radiat Oncol. 2019 Dec;63(6):836-841. (PMID: 31520465)
Pract Radiat Oncol. 2021 Nov-Dec;11(6):515-526. (PMID: 34077809)
J Contemp Brachytherapy. 2017 Apr;9(2):146-150. (PMID: 28533803)
Radiother Oncol. 2019 Dec;141:144-148. (PMID: 31564554)
Brachytherapy. 2016 May-Jun;15(3):283-287. (PMID: 26853354)
Eur Urol. 2021 Sep;80(3):280-292. (PMID: 33309278)
Radiother Oncol. 2019 Dec;141:156-163. (PMID: 31570236)
Int J Radiat Oncol Biol Phys. 2015 Aug 1;92(5):971-977. (PMID: 26054865)
Int Urol Nephrol. 2019 Jul;51(7):1101-1106. (PMID: 30977019)
JAMA. 2012 Apr 18;307(15):1611-20. (PMID: 22511689)
Pract Radiat Oncol. 2022 Nov-Dec;12(6):e531-e537. (PMID: 35718075)
Int J Radiat Oncol Biol Phys. 2006 Mar 1;64(3):817-24. (PMID: 16297567)
Front Oncol. 2022 Aug 26;12:971344. (PMID: 36091157)
Clin Transl Radiat Oncol. 2020 Dec 11;27:1-7. (PMID: 33364450)
Int J Radiat Oncol Biol Phys. 2013 Jun 1;86(2):324-9. (PMID: 23474112)
J Contemp Brachytherapy. 2019 Feb;11(1):8-13. (PMID: 30911304)
Int J Radiat Oncol Biol Phys. 2007 Mar 15;67(4):1106-12. (PMID: 17197119)
Int J Radiat Oncol Biol Phys. 2013 Aug 1;86(5):842-7. (PMID: 23845840)
Int J Radiat Oncol Biol Phys. 2016 Oct 1;96(2):318-322. (PMID: 27475672)
Brachytherapy. 2017 Jan - Feb;16(1):186-192. (PMID: 28341011)
Brachytherapy. 2010 Oct-Dec;9(4):328-34. (PMID: 20116341)
معلومات مُعتمدة: P30 CA006927 United States CA NCI NIH HHS
فهرسة مساهمة: Keywords: Dosimetry; High dose-rate brachytherapy; Prostate cancer; Rectal hydrogel spacer; Reirradiation; Salvage therapy
المشرفين على المادة: 0 (Hydrogels)
تواريخ الأحداث: Date Created: 20230701 Date Completed: 20231102 Latest Revision: 20231103
رمز التحديث: 20231104
مُعرف محوري في PubMed: PMC10527788
DOI: 10.1016/j.brachy.2023.06.003
PMID: 37393186
قاعدة البيانات: MEDLINE
الوصف
تدمد:1873-1449
DOI:10.1016/j.brachy.2023.06.003